Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias

Citation
Mj. Domanski et al., Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias, J AM COL C, 34(4), 1999, pp. 1090-1095
Citations number
17
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN journal
07351097 → ACNP
Volume
34
Issue
4
Year of publication
1999
Pages
1090 - 1095
Database
ISI
SICI code
0735-1097(199910)34:4<1090:REOTIC>2.0.ZU;2-2
Abstract
OBJECTIVES We sought to assess the effect of baseline ejection fraction on survival difference between patients with life-threatening ventricular arrh ythmias who were treated with an antiarrhythmic drug (AAD) or implantable c ardioverter-defibrillator (ICD). BACKGROUND The Antiarrhythmics Versus Implantable Defibrillators (AVID) stu dy demonstrated improved survival in patients with ventricular fibrillation or ventricular tachycardia with a left ventricular ejection fraction (LVEF ) less than or equal to 0.40 or hemodynamic compromise, METHODS Survival differences between AAD-treated and ICD-treated patients e ntered into the AVID study (patients presenting with sustained ventricular arrhythmia associated with an LVEF less than or equal to 0.40 or hemodynami c compromise) were compared at different levels of ejection fraction. RESULTS In patients with an LVEF greater than or equal to 0.35, there was n o difference in survival between AAD-treated and ICD-treated patients. A te st for interaction was not significant, but had low power to detect an inte raction. For patients with an LVEF 0.20 to 0.34, there was a significantly improved survival with ICD as compared with AAD therapy. In the smaller sub group with an LVEF <0.20, the same magnitude of survival difference was see n as that in the 0.20 to 0.34 LVEF subgroup, but the difference did not rea ch statistical significance. CONCLUSIONS These data suggest that patients with relatively well-preserved LVEF (greater than or equal to 0.35) may not have better survival when tre ated with the ICD as compared with AADs. At a lower LVEF, the ICD appears t o offer improved survival as compared with AADs, Prospective studies with l arger patient numbers are needed to assess the effect of relatively well-pr eserved ejection fraction (greater than or equal to 0.35) on the relative t reatment effect of AADs and the ICDs. (J Am Coll Cardiol 1999;34:1090-5) (C ) 1999 by the American College of Cardiology.